Author/Authors :
Ravindranathan, Deepak Department of Medicine - Emory University School of Medicine - Atlanta - GA, USA , Hitron, Emilie Elise Department of Hematology and Medical Oncology - Winship Cancer Institute of Emory University - Atlanta - GA, USA , Russler, Greta Anne Department of Hematology and Medical Oncology - Winship Cancer Institute of Emory University - Atlanta - GA, USA , Bilen, Mehmet Asim Department of Hematology and Medical Oncology - Winship Cancer Institute of Emory University - Atlanta - GA, USA , Xue, Yue Department of Pathology - Emory University School of Medicine - Atlanta - GA, USA
Abstract :
A paraneoplastic syndrome can often present as the first manifestation of an underlying malignancy. We report a patient whopresented with cholestatic jaundice as a paraneoplastic syndrome from his newly diagnosed metastatic prostate cancer. Hereceived initial treatment with androgen deprivation therapy followed by six cycles of docetaxel resulting in resolution of hischolestatic process, normalization of liver enzyme levels, and excellent biochemical and radiographic response. To the best of ourknowledge, this is the first reported case of metastatic prostate cancer with cholestatic jaundice as a paraneoplastic phenomenon tobe safely treated with androgen deprivation therapy and upfront docetaxel, reflecting the latest shift in the treatment of metastaticprostate cancer.
Keywords :
Metastatic Prostate Cancer Manifesting , Cholestatic Jaundice , ADT , PSA
